Strides Arcolab, one of the largest exporters of branded generic pharmaceutical products in India, has announced receipt of ANDA approval for Flumazenil Injection USP. 0.1 mg / ml multiple dose vial. Flumazenil Injection is indicated for the complete or partial reversal of the sedative effects of benzodiazepines.

The product is licensed to Akorn-Strides, LLC, which is a Joint Venture formed in 2004 by Akorn, Inc. and Strides Arcolab Ltd.

The primary mission for the Joint Venture is to develop liquid, lyophilized and dry powder formulations of generic injectable products targeting several therapeutic markets with a major focus on anti-infective, analgesics and CNS medicines.

Strides Acrolab has a major presence in various developing countries such as Africa, Latin America and Asia as well as in developed markets such as the U.S., Canada and part of Europe. The company is one of the largest Indian suppliers of institutionally funded aid projects and is an approved supplier to the Global Drug Facility, UNICEF, and MSF amongst others.